Smoking cessation and the risk of cardiovascular disease outcomes predicted from established risk scores: Results of the Cardiovascular Risk Assessment among Smokers in Primary Care in Europe (CV-ASPIRE) Study by Pablo Mallaina et al.
Mallaina et al. BMC Public Health 2013, 13:362
http://www.biomedcentral.com/1471-2458/13/362RESEARCH ARTICLE Open AccessSmoking cessation and the risk of cardiovascular
disease outcomes predicted from established
risk scores: Results of the Cardiovascular Risk
Assessment among Smokers in Primary Care in
Europe (CV-ASPIRE) Study
Pablo Mallaina1*, Christos Lionis2, Hugo Rol3, Renzo Imperiali4, Andrew Burgess5, Mark Nixon5
and Franco Mondello Malvestiti1Abstract
Background: Smoking is a major risk factor for cardiovascular disease (CVD). This multicenter, cross-sectional survey
was designed to estimate the cardiovascular (CV) risk attributable to smoking using risk assessment tools, to better
understand patient behaviors and characteristics related to smoking, and characterize physician practice patterns.
Methods: 1,439 smokers were recruited from Europe during 2011. Smokers were ≥40 years old, smoked > 10
cigarettes/day and had recent measurements on blood pressure and lipids. CV risk was calculated using the SCORE
system, Framingham risk equations, and Progetto CUORE model. The CV risk attributable to smoking was evaluated
using a simulated control (hypothetical non-smoker) with identical characteristics as the enrolled smoker. Risks
assessed included CV mortality, coronary heart disease (CHD), CVD and hard CHD. Demographics, comorbidities,
primary reasons for consultation, behavior towards previous attempts to quit, and interest in smoking cessation was
assessed. Dependence on nicotine was evaluated using the Fagerström Test for Nicotine Dependence. GP practice
patterns were assessed through a questionnaire.
Results: The prediction models consistently demonstrated a high CV risk attributable to smoking. For instance, the
SCORE model demonstrated that this study population of smokers have a 100% increased probability of death due
to cardiovascular disease in the next 10-years compared to non-smokers. A considerable amount of patients would
like to hear from their GP about the different alternatives available to support their quitting attempt.
Conclusions: The findings of this study reinforce the importance of smoking as a significant predictor of long-term
cardiovascular events. One of the best gains in health could be obtained by tackling the most important modifiable
risk factors; these results suggest smoking is among the most important.
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Tobacco is the only legally available consumer product
which kills up to one in every two users when used as
intended [1]. Smoking kills over 650,000 people in the
European Union every year [2]. Smoking is a major risk
factor for CVD, and can result in a seven-fold increase
in the risk of peripheral arterial disease and at least a
two-fold increase in the risk of coronary artery disease
[3-5]. The INTERHEART study showed that if a person
stopped smoking, they reduced their risk of myocardial
infarction by about 65% [6].
Several multi-factorial risk models have been devel-
oped to assess the risk for development of CVD, and all
of these models include tobacco use as an important
predictor, along with age, blood pressure and cholesterol
levels, highlighting the impact of smoking on cardiovas-
cular risk. The Framingham Risk Score quantifies the
absolute level of CVD risk based on a number of risk
factors [7]. In addition to CVD risk, there have been
multiple models proposed using the Framingham data
to calculate various other absolute risk levels, including
CVD mortality, coronary heart disease, intermittent clau-
dication and recurring coronary heart disease [8-12].
In Europe, the Systematic COronary Risk Evaluation
(SCORE) system was initiated to develop a risk scoring
system for the management of cardiovascular risk in
European clinical practice. The SCORE data contains ap-
proximately 3 million person-years of observation from
205,178 subjects [13-16].
General practitioners (GPs) in primary care practice
play an important role in smoking cessation through
measures such as counseling and pharmacotherapy [16].
Research has shown that simple advice provided by GPs
can help substantially increase smoking cessation rates
[17]. Data from studies on self-reports by GPs show that
while the majority of GPs (62% to 98%) question all new
patients as to their smoking status, the proportion of
GPs offering more intensive interventions or prescribing
treatments for cessation is generally lower, and also has
shown to differ across and within countries [18-21].
Studies have found that the rates of GPs providing
smoking cessation advice vary across European countries
[18,19,22,23]. Moreover, GP’s engagement in providing
smoking cessation advice to patients depends on factors
such as the GP’s smoking status, their attitude towards
smoking, their relationship with the patient, and their
knowledge of existing smoking cessation interventions
[21,24]. Researchers advocate the development of country-
specific strategies for encouraging and supporting a GP’s
smoking cessation activity [21].
We performed this European, multi-centre, observa-
tional, cross-sectional survey of smokers in the primary
care setting to provide estimates of the risk of CVD
among the smoking population attending primary carein Europe, using standard risk assessment tools. This
study also reports on patient behaviors related to smoking
as well as physicians practice patterns.
Methods
We performed this cross-sectional survey involving smokers
in the primary care setting, selected from 3 European
countries (Greece, Italy and Netherlands). These countries
were chosen because they met the study data require-
ments and provided a geographic spread within Europe in
an attempt to create a dispersed distribution. GPs were
required to routinely collect lipid levels and blood pres-
sure from smokers as standard practice based on their
availabilities, their acceptance to the protocol and in-
formed consent form and their ability to enroll the target
population based on their response to their following
questions:
 How many smoker patients 40 years or older does
the physician see per day/per week/per months?
 Can the investigator enroll 15 smoker patients
(who smoke at least 10 cigarettes per day)?
 How long the investigator expect he will need to
enroll 15 consecutive smoker patients (who smoke
at least 10 cigarettes per day)?
Out of 720 possible sites, 229 met these criteria and
were selected.
The final protocol and case report form, any amend-
ments, and informed consent documentation were reviewed
and approved by regulatory authorities required in each
country.
Participating GPs assessed all smoker patients 40 years
or older for their suitability for enrolment into the sur-
vey at the time that they attended the centre regardless
of their reason for the consultation. Patients were se-
lected consecutively from the patients that visited their
doctor on a routine basis irrespective of the reason for
their visit. The recruitment period for the survey was
flexible to enable a maximum of 15 patients per GP.
There was no set time limits for recruitment into this
study. Patient recruitment continued until there were
sufficient patients (approx 1400) to provide adequate
precision for the study endpoints. Informed consent was
obtained for those patients who met the study inclusion/
exclusion criteria and who agreed to participate. Suitable
patients smoked at least 10 cigarettes per day during the
previous month and had blood pressure and lipids level
data in their clinical records (within the last 12 months).
Once informed consent was obtained, the investiga-
tor administered the survey to patients and completed
the study case report form. Demographic information
was collected on age, gender, height and weight. La-
boratory parameters included total cholesterol, High-
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and systolic and diastolic blood pressure. Information
on medical history was also captured (history of cardio-
vascular disease, diabetes, hypertension, hypercholes-
terolemia and chronic obstructive pulmonary disease
(COPD)) including reason for consultation and family
medical history.
Patients were asked whether they had persistent chronic
cough, excess mucous and phlegm, shortness of breath,
or wheezing, and whether they were currently being
treated for hypertension, hypercholesterolemia, diabetes,
or COPD. Parameters on patient behaviors related to
smoking included the Fagerström Test for Nicotine De-
pendence (FTND) [25], years of smoking, previous at-
tempts to quit smoking, previous use of any smoking
cessation programs, longest time without smoking, inter-
est in quitting smoking, and interest in type of smoking
cessation support. Practice patterns related to smoking
behavior included asking the patient whether they were
provided with smoking cessation advice and whether any
behavioral or pharmacotherapy support was offered.Table 1 Description of study endpoints and associated risk sc
Risk score Study endpoint Study population Stu
SCOREa Cardiovascular
Mortality Risk
Smokers attending primary care




Smokers attending primary care




Smokers attending primary care




Smokers attending primary care




Smokers attending primary care





primary care in Europe; age 39 to





Risk of Coronary or
Cardiovascular Event
Smokers attending primary care
in Europe; age 39 to 69 years.
111
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ing number of practitioners, patient volume and phys-
ician smoking status. To assess typical clinical practice
patterns related to smoker behavior, we asked the clin-
ician whether typically in their practice smoking ces-
sation advice, behavior support or pharmacotherapy is
offered to patients who have an interest in quitting
smoking.
Statistical analysis
Continuous variables were summarized using mean and
standard deviation (SD), and categorical variables were
summarized using counts and proportions. 95% confi-
dence intervals were calculated where appropriate.
For smokers, 10-year cardiovascular risk was calcu-
lated using multiple tools and models including various
Framingham risk scores, SCORE, and the CUORE risk
score [8-13]. The cardiovascular disease risk scores used
in this study are summarized in Table 1. To compare the
predicted probability of a cardiovascular event calculated
using these scores against those for non-smokers; weore, CV ASPIRE study, Europe, 2011
dy sample size Risk
period
Predictors
9 10 years Age, gender, systolic blood pressure, total
cholesterol
5 10 years Age, gender, diabetes status, systolic and
diastolic blood pressure, total cholesterol,
LDL cholesterol
8 10 years Age, gender, diabetes status, systolic blood
pressure, treatment of hypertension, total
cholesterol, LDL and HDL cholesterol
2 10 years Age, gender, systolic blood pressure,
treatment of hypertension, total cholesterol,
HDL cholesterol
1 4 years Age, gender, systolic blood pressure,
treatment of hypertension, total cholesterol,
coronary heart disease, number of cigarettes
smoked per day
2 years Age, gender, diabetes status, systolic blood
pressure, fasting total cholesterol, fasting
HDL cholesterol
7 10 years Age, gender, diabetes status, systolic blood
pressure, total cholesterol, HDL cholesterol,
treatment of hypertension
n-year risk of fatal cardiovascular disease in Europe: the SCORE project.
g risk factor categories. Circulation 1998;97(18):1837–1847.
for use in primary care: the Framingham Heart Study. Circulation
ronary heart disease prediction scores: results of a multiple ethnic groups
profile from the Framingham Heart Study. Circulation 1997;96(1):44–49.
appraisal: new results from the Framingham Study. Am Heart J 2000;
lobale assoluto: il punteggio individuale del Progetto CUORE. Annali dellIstituto
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smoker as a non-smoker. Risk differences were calcu-
lated by taking the difference of the predicted probabil-
ities between smokers and non-smokers. Relative risk
estimates were calculated by dividing the predicted
probability for smokers by the non-smokers.
All analyses were performed using SASW Version 9.2
(Cary, NC).
Results
Participating sites and participants
A total of 1439 subjects were enrolled in the study
(Greece n=571; Italy n=443, and Netherlands n=425)
from 104 sites. A summary of site demographics is shown
in Table 2.
Descriptive characteristics of participants. On average,
3.8 practitioners per site enrolled patients and the mean
patient volume per day was 71.1.
Patients from Greece were, on average younger, than
those from Italy or Netherlands; patients from Greece had
a mean age of 55.6 years, Italy 58.2 years and Netherlands
59.2 years (Table 3). The most common reason for
consultation was general medical examination (45.3%),
followed by a cardiovascular related reason (16.2%). The
primary reason for consultation varied across countries:
for Greece and Italy General medical examination was the
most frequent reason (57.2% and 57.1%, respectively),
for Netherlands this was 16.1%, with the most frequent
reason being Cardiovascular related (31.7%). Similarly, a
higher proportion of patients in the Netherlands (13.1%)
visited their GP for pulmonary related conditions com-
pared to Greece (8.8%) or Italy (4.9%). Mean fasting total
cholesterol, HDL and LDL values at baseline were 5.4
mmol/L, 1.3 mmol/L and 3.4 mmol/L, respectively. The
mean total cholesterol and LDL were both above the
recommended optimal level for the general population
(European Cholesterol Guidelines (2003), optimal choleste-Table 2 Site demographics by Country, CV ASPIRE study, Euro
Characteristic Greece (N=38
Mean number of practitioners at site (range) 7.2 (1–20)
Mean typical patient volume per day (range) 127.4 (25–400)
Mean participating physician years of practice (range) 18.2 (10–35)




Mean total number of smoker patients 40 years or
older screened to enroll 15 study patients (range)
27.0 (15–70)
Median time taken to enroll 15 patients (days), (range) 20.0 (3–90)
Mean number of patients that met inclusion/exclusion
criteria but did not show interest in participating
in study (range)
3.6 (0–15)rol <5.0 mmol/L, optimal LDL <3.0 mmol/L). Mean sys-
tolic blood pressure was 135.5 mmHg and diastolic blood
pressure 81.6 mmHg, which are both above the normal
limits (European Cholesterol Guidelines (2007): normal
systolic blood pressure: 120–129 mmHg, normal diastolic
blood pressure: 80–84 mmHg).
Comorbid conditions
The most commonly reported medical history categor-
ies were hypertension (54.4%) and hypercholesterolemia
(50.5%), the majority of whom were currently receiving
medication for their disease (85.4% for hypertension,
67.5% for hypercholesterolemia) (Table 3). 33.1% of pa-
tients reported persistent chronic cough. Excess mucous
and phlegm, shortness of breath and wheezing were also
reported by 19.6%, 29.9% and 14.5% of patients, respect-
ively. 48.7% of patients reported at least 1 COPD related
disorder. Results differed across countries. Cardiovascu-
lar diseases, diabetes and COPD were more common in
Netherlands (32.2%, 30.6%, and 26.8% of patients, res-
pectively) compared to Greece (17.0%, 17.5%, and 14.2% of
patients, respectively) and Italy (15.6%, 16.7%, and 19.9%
of patients, respectively). A higher number of patients
were being treated with medication for diabetes and
COPD in the Netherlands (25.2% and 20.2% of patients,
respectively) compared to Greece (15.4% and 8.4% of pa-
tients, respectively) and Italy (14.7% and 11.1% of pa-
tients, respectively).
Cardiovascular risk assessments
Results of the cardiovascular risk assessments based on
the prediction scores are shown in Table 4.
The SCORE model for 10-year cardiovascular mortal-
ity risk, predicts a 100% increase among smokers (4%)
attending primary care in the participating European
countries compared to the risk had they been non-
smokers (2%).pe, 2011
) Italy (N=31) Netherlands (N=35) Total (N=104)
1.7 (1–6) 1.7 (1–5) 3.8 (1–20)
28.0 (7–80) 42.5 (20–180) 71.1 (7–400)
29.5 (11–44) 22.5 (5–40) 22.9 (5–44)
2 (6.9%) 2 (6.5%) 4 (4.1%)
13 (44.8%) 11 (35.5%) 36 (36.7%)
14 (48.3%) 18 (58.1%) 58 (59.2%)
23.8 (4–50) 22.5 (3–50) 24.7 (3–70)
20.0 (0–365) 79.5 (3–365) 25.0 (0–365)
8.4 (0–30) 26. (0–15) 4.7 (0–30)
Table 3 Patient characteristics of smokers by Country, CV ASPIRE study, Europe, 2011
Characteristic Greece (N=571) Italy (N=443) Netherlands (N=425) Total (N=1439)
Mean age, years (age range) 55.6 (39–91) 58.2 (39–85) 59.2 (40–85) 57.4 (39–91)
Gender, n (%)
Male 352 (61.5%) 263 (58.8%) 199 (46.7%) 814 (56.3%)
Female 220 (38.5%) 184 (41.2%) 227 (53.3%) 631 (43.7%)
Mean BMI, kg/m2 (range) 27.6 (12–54) 26.0 (17–43) 27.5 (16–54) 27.1 (12–54)
Primary reason for seeking medical advice, n (%)
General medical examination 319 (57.2%) 249 (27.1%) 64 (16.1%) 629 (45.3%)
Cardiovascular related 68 (12.2%) 31 (7.2%) 126 (31.7%) 225 (16.2%)
Psychiatric related 15 (2.7%) 14 (3.2%) 20 (5.0%) 49 (3.5%)
Pulmonary related 49 (8.8%) 21 (4.9%) 52 (13.1%) 122 (8.8%)
Gastrointestinal related 34 (6.1%) 34 (7.9%) 12 (3.0%) 80 (5.8%)
Metabolic related 46 (8.2%) 29 (6.7%) 37 (9.3%) 112 (8.1%)
Prescription 22 (3.9%) 6 (1.4%) 1 (0.3%) 29 (2.1%)
Other 12 (2.2%) 57 (13.2%) 89 (22.4%) 158 (11.4%)
Lipid levels
Mean total cholesterol, mmol/L (SD) 5.7 (1.19) 5.4 (1.27) 5.2 (1.19) 5.5 (1.24)
Mean HDL cholesterol, mmol/L (SD) 1.3 (0.38) 1.3 (0.37) 1.3 (0.59) 1.3 (0.45)
Mean LDL cholesterol, mmol/L (SD) 3.7 (1.05) 3.3 (0.89) 3.2 (1.10) 3.4 (1.04)
Blood pressure
Systolic blood pressure, mmHg (SD) 135.5 (18.65) 130.9 (14.59) 140.4 (17.42) 135.5 (17.50)
Diastolic blood pressure, mmHg (SD) 82.5 (9.70) 78.7 (8.24) 83.2 (10.63) 81.6 (9.75)
Medical history, n (%)
Cardiovascular diseases 97 (17.0%) 69 (15.6%) 137 (32.2%) 303 (21.1%)
Diabetes 100 (17.5%) 74 (16.7%) 130 (30.6%) 304 (21.1%)
Hypertension 353 (61.8%) 192 (43.3%) 238 (56.0%) 783 (54.4%)
Hypercholesterolemia 372 (65.1%) 161 (36.3%) 193 (45.4%) 726 (50.5%)
Chronic obstructive pulmonary disease 81 (14.2%) 88 (19.9%) 114 (26.8%) 283 (19.7%)
Currently treated with medication (yes), n (%)
Diabetes 88 (15.4%) 65 (14.7%) 107 (25.2%) 260 (18.1%)
Hypertension 280 (49.0%) 184 (41.5%) 205 (48.2%) 669 (46.5%)
Hypercholesterolemia 240 (42.0%) 97 (21.9%) 153 (36.0%) 490 (34.1%)
Chronic obstructive pulmonary disease 48 (8.4%) 49 (11.1%) 86 (20.2%) 183 (12.7%)
Family medical history, n (%)
Cardiovascular diseases 205 (35.9%) 100 (22.6%) 129 (30.4%) 434 (30.2%)
Diabetes 168 (29.4%) 77 (17.4%) 91 (21.4%) 336 (23.3%)
Hypertension 280 (49.0%) 138 (31.2%) 107 (25.2%) 525 (36.5%)
Hypercholesterolemia 205 (35.9%) 76 (17.2%) 70 (16.5%) 351 (24.4%)
Chronic obstructive pulmonary disease 66 (11.6%) 23 (5.2%) 59 (13.9%) 148 (10.3%)
Number of medical conditions, n (%)
No conditions 105 (18.4%) 145 (32.7%) 75 (17.6%) 325 (22.6%)
1 condition 136 (23.8%) 126 (28.4%) 107 (25.2) 369 (25.6%)
2 condition 181 (31.7%) 96 (21.7%) 100 (23.5%) 377 (26.2%)
3 condition 100 (17.5%) 43 (9.7%) 81 (19.1%) 224 (15.6%)
4 condition 40 (7.0%) 28 (6.3%) 48 (11.3%) 116 (8.1%)
5 condition 9 (1.6%) 5 (1.1%) 14 (3.3%) 28 (1.9%)
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Table 3 Patient characteristics of smokers by Country, CV ASPIRE study, Europe, 2011 (Continued)
Other disorder characteristics, n (%)
Persistent chronic cough 214 (37.6%) 138 (31.7%) 121 (28.5%) 473 (33.1%)
Excess mucous and phlegm 115 (20.3%) 64 (14.7%) 101 (23.8%) 280 (19.6%)
Shortness of breath 217 (38.2%) 104 (23.9%) 106 (25.0%) 427 (29.9%)
Wheezing 95 (16.8%) 45 (10.3%) 67 (15.8%) 207 (14.5%)
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disease risk, predicts a 50% increase among smokers
(17.9%) attending primary care in the participating
European countries compared to the risk had they been
non-smokers (11.9%). The Framingham model also pre-
dicts a 32% increase (from 16.0% to 21.2%) in the 10-
year CVD risk. For the 10-year hard coronary heart
disease risk, the Framingham model predicts a 65% in-
crease (from 8.0% to 13.2%). According to the model,
smokers in Greece showed a slightly higher (15%) risk
attributable for hard coronary heart disease to smoking
(72%) compared to those in Italy (57%) and 11% higher
than Netherlands (61%). The 4-year intermittent claudi-
cation risk using the Framingham model is predicted to
increase by 87% (from 1.5% to 2.8%).
For the Framingham 2-year recurring coronary heart
disease risk model, the analyses population is patients
with at least one coronary heart disease event. As smok-
ing status is not included in the model for males, the es-
timated risk for males were not calculated. For females
with a previous coronary event, the model predicts in
smokers a 40% increase (from 4.5% to 6.4%) in the 2-
year recurring coronary heart disease.
The Progetto model for 10-year risk of a coronary or
cardiovascular event, predicts a 68% increase (from 6.2%
to 10.3%).Table 4 Cardiovascular risk assessments of smokers, CV ASPIR
Cardiovascular risk Risk score n Smok
(N=1
10-year Cardiovascular Mortality Risk,
mean % (range)
SCORE 1419 4.0%
10-year Coronary Heart Disease Risk,
mean % (range)
Framingham 1275 17.9%
10-Year Cardiovascular Disease Risk,
mean % (range)
Framingham 1368 21.2%
10-Year Hard Coronary Heart Disease Risk,
mean % (range)
Framingham 1372 13.2%
4-Year Intermittent Claudication Risk,
mean % (range)
Framingham 1161 2.8%
2-Year Recurring Coronary Heart Disease Risk
(amongst females with history of CHD),
mean % (range)
Framingham 68 6.4%
10-Year Risk (%) of Coronary or Cardiovascular
Event, mean % (range)
Progetto
CUORE
1117 10.3%Patient behaviors related to smoking
The mean (SD) FTND score for all patients was 5.0
(2.40) (Table 5). The mean FTND score was higher in
Greece (5.7, 95% Confidence interval (CI): 5.5, 5.9) com-
pared to Italy (4.5, 95% CI: 4.3, 4.8) and Netherlands
(4.7, 95% CI: 4.5, 4.9).
It was observed that 70.3% of patients had previously
attempted to quit smoking, however, only 23% of pa-
tients had previously used any smoking cessation pro-
grams. Nicotine replacement therapy (15.0%) was the
most common, followed by prescription medicine (5.2%)
and then alternative medicine (5.1%). The mean number
of years smoking was 35.2 years with differences among
countries. Furthermore, a relatively higher percentage of
patients in Greece (83.3%) were interested in quitting
smoking compared with patients in Italy (63.9%) and
Netherlands (69.7%).
Clinical practice patterns
Overall, 65 out of 98 practices (66.3%) typically offer
smoking cessation advice to all smokers and the other
33.7% offer advice to some selected smokers (Table 6). Be-
havioral support was typically offered to all smokers who
want to quit in 77.6% of practices, and pharmacotherapy
support in 71.4%. In Greece and Netherlands, smoking









(0%-26%) 2.0% (0%-14%) 2.0% 100%
(1%-84%) 11.9% (1%-66%) 6.0% 50%
(2%-30%) 16.0% (1%-30%) 5.1% 32%
(0%-49%) 8.0% (0%-48%) 5.2% 65%
(0%-36%) 1.5% (0%-20%) 1.3% 87%
(2%-21%) 4.5% (1%-15%) 1.8% 40%
(0%-77%) 6.2% (0%-58%) 4.2% 68%
Table 5 Patient behaviors related to smoking by Country, CV ASPIRE study, Europe, 2011
Characteristic Greece (N=571) Italy (N=443) Netherlands (N=425) Total (N=1439)
Fagerström total score, n (%) 552 421 402 1375
Low dependence on nicotine 104 (18.8%) 146 (34.7%) 116 (28.9%) 366 (26.6%)
Moderately dependent on nicotine 239 (43.3%) 179 (42.5%) 205 (51.0%) 623 (45.3%)
Highly dependent on nicotine 209 (37.9%) 96 (22.8%) 81 (20.1%) 386 (28.1%)
Number of years smoking, mean (SD) 31.3 (11.90) 35.5 (12.00) 40.0 (12.21) 35.2 (12.53)
Previously attempted to quit smoking, n (%) 568 441 419 1428
Yes 392 (69.0%) 274 (62.1%) 338 (80.7%) 1004 (70.3%)
No 176 (31.0%) 167 (37.9%) 81 (19.3%) 424 (29.7%)
Number of previous attempts to quit, mean (SD) 2.7 (2.50) 3.0 (3.18) 3.0 (2.87) 2.9 (2.83)
Previous cessation support methods used, n (%) 544 404 396 1344
None 449 (82.5%) 328 (81.2%) 254 (64.1%) 1031 (76.7%)
Nicotine replacement therapy 56 (10.3%) 47 (11.6%) 98 (24.7%) 201 (15.0%)
Behavioral therapy 15 (2.8%) 17 (4.2%) 9 (2.3%) 41 (3.1%)
Alternative medicine 20 (3.7%) 19 (4.7%) 30 (7.6%) 69 (5.1%)
Prescription medicine 29 (5.3%) 6 (1.5%) 35 (8.8%) 70 (5.2%)
Other 5 (0.9%) 11 (2.7%) 17 (4.3%) 33 (2.5%)
Currently interested in quitting smoking, n (%) 562 438 416 1416
Yes 468 (83.3%) 280 (63.9%) 290 (69.7%) 1038 (73.3%)
No 94 (16.7%) 158 (36.1%) 126 (30.3%) 378 (26.7%)
Interest shown in the following cessation support methods, n (%) 537 326 348 1211
None 177 (33.0%) 118 (36.2%) 101 (29.0%) 396 (32.7%)
Nicotine replacement therapy 59 (11.0%) 47 (14.4%) 81 (23.3%) 187 (15.4%)
Behavioral therapy 122 (22.7%) 85 (26.1%) 43 (12.4%) 250 (20.6%)
Alternative medicine 24 (4.5%) 30 (9.2%) 18 (5.2%) 72 (5.9%)
Prescription medicine 212 (39.5%) 92 (28.2%) 114 (32.8%) 418 (34.5%)
Other 12 (2.2%) 10 (3.1%) 33 (9.5%) 55 (4.5%)
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compared to Italy (48.3%). Pharmacotherapy support was
offered in a higher percentage of Netherlands (87.1%) and
Italy (82.8%) practices compared to Greece (50.0%).
Physician practice patterns
At the study visit, 1125 out of 1433 patients (78.5%) were
provided with smoking cessation advice and 50.8% were
offered behavioral support to help them quit smokingTable 6 Clinical practice patterns by Country, CV ASPIRE stud
Clinical practice response Greece (N=
Typically in your practice, is smoking cessation advice
offered to smokers? n (%)
38
Yes to all smokers 29 (76.3%)
Yes to some selected smokers 9 (23.7%)
Not offered 0
Typically in your practice, is any behavioral support
offered to all smokers who want to quit smoking? n (%)
27 (71.1%)
Typically in your practice, is any pharmacotherapy support
offered to all smokers who want to quit smoking? n (%)
19 (50.0%)(Table 7). Only 23.9% of patients were offered pharmaco-
therapy. The percentage of patients that were offered
behavioral support was similar by country. However, a rela-
tively higher percentage of patients in Greece (87.9%) were
provided with smoking cessation advice compared with
Italy (73.2%) and Netherlands (71.5%). Whereas, a relative-
ly lower percentage of patients in Greece (13.2%) were of-
fered pharmacotherapy compared with Italy (24.2%) and
Netherlands (37.7%).y, Europe, 2011
38) Italy (N=31) Netherlands (N=35) Total (N=104)
29 31 98
14 (48.3%) 22 (71.0%) 65 (66.3%)
15 (51.7%) 9 (29.0%) 33 (33.7%)
0 0 0
22 (75.9%) 27 (87.1%) 76 (77.6%)
24 (82.8%) 27 (87.1%) 70 (71.4%)
Table 7 Physician practice patterns by Country, CV ASPIRE study, Europe, 2011
Characteristic Greece (N=571) Italy (N=443) Netherlands (N=425) Total (N=1439)
At this visit, was this patient provided with
smoking cessation advice? n (%)
499 (87.9%) 323 (73.2%) 303 (71.5%) 1125 (78.5%)
At this visit, was any behavioral support
offered for helping quit smoking? n (%)
319 (56.5%) 194 (43.8%) 215 (50.7%) 728 (50.8%)
At this visit, was any pharmacotherapy
offered for helping quit smoking? n (%)
74 (13.2%) 107 (24.2%) 160 (37.7%) 341 (23.9%)
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To our knowledge, CV-ASPIRE was one of the largest
cross-sectional surveys of its kind to explore health risks
and prevalence of comorbidities in smokers in the primary
care setting and where GPs in Europe were surveyed on
issues concerning patient behavior and physician attitudes
toward smoking cessation. As expected, we found both
patient behavior and physician attitudes toward smoking
cessation to vary by country. A possible explanation for
these apparent differences in practice patterns could per-
haps include differences in the attitude towards the role of
GPs in influencing smoking cessation. Differences in the
pattern of practices and the negligence of prevention in
primary care seem to be the explanation for this finding in
some countries [26]. These results are consistent with pre-
vious findings which showed varying rates of GP advice
on smoking cessation across Europe [18,19,22,23].
A total of 49% of smokers reported at least one COPD
related disorder, however only 20% of were reported as
diagnosed with COPD. According to the Global Initia-
tive for Chronic Obstructive Lung Disease COPD refer-
ence guide, “A diagnosis of COPD should be considered
in any individual who has dyspnea, chronic cough or
sputum production, and/or a history of exposure to risk
factors for the disease, especially cigarette smoking” [27].
This finding suggests that COPD may be under diag-
nosed in smokers.
In Greece and Italy, the primary reason for consult-
ation with their GP was general medical examination
(57%); this was notably higher than in the Netherlands
(16%), where the primary reason for consultation was
cardiovascular related (32%). One of the factors that may
help explain this is that more patients may be visiting
their GP in Italy and Greece in order to obtain a repeat
prescription. In rural Greece it has been shown that over
half of patients visit their GP solely to ask for a prescrip-
tion, and 70% of prescriptions are renewal of an older
one [28].
Interestingly, the perception of GPs and patients dif-
fered with regards to the types of smoking advice offered
to smokers in the primary care setting. For instance, a
higher proportion (73%) of Italian patients reported that
their GPs offered smoking advice compared to Italian
GPs themselves (48%). The referral for behavioral support
and pharmacotherapy was reported in the 3 participantcountries consistently lower by patients than by GPs. Per-
haps the difference in reporting rates could be explained
in part by recall bias where GPs more readily remember
the delivery of service rather than their failure to offer the
service. They could also be explained through prevarica-
tion bias such that GPs could be more inclined to state
that they offered the advice to their patients while patients
are more inclined to deny that such advice was ever of-
fered to them.
Demographic characteristics were for the most part
distributed similarly by country (Table 3).
Various prediction models were employed in this study
to estimate the absolute risk of outcomes previously
established to be associated with smoking. A hypothet-
ical population of non-smokers, derived directly from
the prediction model (by setting smoking status to non-
smoking), was applied in these models. This approach
allowed us to mimic a counterfactual scenario where an
identifiable cohort of smokers could be classed as non-
smokers. The main advantage of generating a hypothet-
ical population of non-smokers from a prediction model
is that it avoids the need for sampling non-smokers into
the study. Moreover, it also provides control of all con-
founders included as part of the prediction model since
the prediction model assumes that only those variables
included in the model are relevant for the prediction of
events.
A limitation of this approach, however, is that the
model may underperform in the real-world setting given
that any known confounding factor not included in the
prediction model or an unknown confounding factor may
influence outcomes. For instance, the SCORE model only
considers age, gender, smoking status, systolic blood pres-
sure, and lipid levels to be important in the prediction of
death due to cardiovascular disease and ignores potential
important covariates such as alcohol use, family history,
diet, exercise, and concomitant medications. Moreover,
these prediction models do not provide complete infor-
mation about what might have happened if a long-term
smoker was to quit smoking, since the models themselves
do not account for past exposure to smoking and its po-
tential effects on future outcome. Another limitation, is
that the simulated non-smokers have identical blood pres-
sure and lipid levels as the smokers. It has been found
that smokers tend to have lower HDL [3] and higher
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tion is not accounting for this, the results may be consid-
ered a conservative estimate of the impact on CV risk of
smoking.
Despite these limitations, the simulated population of
non-smokers provided a convenient population from which
to derive the relative risk attributable to smoking for car-
diovascular events. The relative risk was reported in this
study because it quantifies the risk in a clear and interpret-
able percentage that can easily be related to the impact of
smoking on cardiovascular events.
The prediction models found expectedly that smokers
experienced a quantitatively higher level of risk in each
of the cardiovascular event categories considered when
compared to a hypothetical population of non-smokers
sharing the same risk factor profile. The directionality of
the association was consistent (i.e., smokers were always
found to be at higher risk) regardless of the prediction
model. We were able to predict, for instance, through the
SCORE model that this study population of smokers have
a 100% increased probability of death due to cardiovas-
cular disease in the next 10-years compared to non-
smokers. The relative risk derived using the Framingham
models for 10-year risk of coronary heart disease and 10-
year risk for “hard” coronary heart disease showed an in-
crease in risk of 50% (from 12% to 18%) and 65% (from
8% to 13%), respectively. The Progetto CUORE model
found a similar risk increase of 68% (from 6% to 10%) for
coronary or cardiovascular events.
The discrepancy in results across the prediction models
just described can be explained by differences in the out-
come of interest. None of the scores predicted risks are
directly comparable. For example, the SCORE model pre-
dicts death due to cardiovascular disease whereas the
Framingham coronary heart disease score predicts new
cardiovascular events, not necessarily resulting in death.
Similarly, the Progetto model predicts the risk of a major
cardiovascular event, in comparison to the Framingham
coronary heart disease model which predicts the risk of
coronary heart disease, and one would not expect all pa-
tients diagnosed with coronary heart disease to necessarily
experience a major event. Another reason why the model
predictions may differ is the underlying population used
to derive the models: the Framingham score was derived
using a population from the United States; the SCORE
model a European and the Progetto an Italian population.
The eligibility criteria for this study was restricted to
individuals 40 years of age or over, which consequently
may limit the generalizability of results to a younger
population or those who have smoked for a shorter dur-
ation of time. Subjects were also required to have avail-
able information on blood pressure and lipids within the
past 12 months of the study. Given that subjects with a
history of cardiovascular disease are more likely to haveavailable measures on the above laboratory parameters,
we expect that this study population would have a higher
prevalence of cardiovascular disease than a general popu-
lation of smokers. Moreover, the generalizability of this
study may be biased towards those at higher risk of CVD.
Conclusions
The findings of this study reinforce the importance of
smoking as a significant predictor of long-term cardiovas-
cular events. The consistency in the elevation of relative
risk found across prediction models reinforces the need
to reduce and eventually eliminate this important source
of morbidity and mortality from the general population
through effective smoking cessation programs. Future
country-specific interventional strategies for smoking ces-
sation should consider targeting GP practices given the
GPs’ role in patient care.
It has been previously shown that smoking is the sec-
ond most important modifiable risk factor associated
with myocardial infarction, after LDL: HDL ratio [30],
and the excess risk of experiencing a heart attack is
halved within a year of quitting in comparison to con-
tinuing smokers [31]. Patients attending GP practices di-
agnosed with hypercholesterolemia are routinely treated
for the condition. However, smokers are far less likely to
receive smoking cessation treatment when visiting their
GP, there may be an unfounded disparity in treatment
for smoking compared to other risk factors. According
to the United States Department of Health and Human
Services “it is difficult to identify any other condition
that presents such a mix of lethality, prevalence. . .and
neglect . . .despite effective and readily available inter-
ventions” [32]. Further analyses may show that one of
the best gains in health could be obtained by tackling
the most important modifiable risk factors, smoking be-
ing one of them. The findings in this study may help fu-
ture strategies for focusing smoking cessation programs
in the primary care setting.
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